T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo

British Journal of Pharmacology

Volumn 140, Issue 7, 2003, Pages 1283-1291

  Mahajan, Hema ^a   Richards, Stephen M ^a   Rattigan, Stephen ^a   Clark, Michael G ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

1 methyl xanthine metabolism; 2 deoxyglucose uptake; Capillary recruitment; Femoral blood flow; Muscle insulin action

Indexed keywords

1 METHYLXANTHINE; 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; CYCLIC GMP PHOSPHODIESTERASE 5 INHIBITOR; DEOXYGLUCOSE; GLUCOSE; INSULIN; METHYL 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINE CARBOXYLATE SULFATE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; FEMORAL ARTERY FLOW; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART RATE; HEMODYNAMICS; IN VIVO STUDY; LEG BLOOD FLOW; LEG MUSCLE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; BLOOD GLUCOSE; GLUCOSE CLAMP TECHNIQUE; HEMODYNAMIC PROCESSES; HYPOGLYCEMIC AGENTS; INSULIN; ISOQUINOLINES; MALE; MUSCLE, SKELETAL; PHOSPHORIC DIESTER HYDROLASES; PYRIDINES; RATS; RATS, WISTAR;

EID: 1642463419     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705548     Document Type: Article

References (39)

1. BALON, T.W. (1999). Integrative biology of nitric oxide and exercise. Exerc. Sport Sci. Rev., 27, 219-253.
2. BALON, T.W. & NADLER, J.L. (1996). Nitric oxide mediates skeletal glucose transport. Am. J. Physiol., 270, E1058-E1059.
3. BALON, T.W. & NADLER, J.L. (1997). Evidence that nitric oxide increases glucose transport in skeletal muscle. J. Appl. Physiol., 82, 359-363.
4. BARON, A.D., LAAKSO, M., BRECHTEL, G., HOIT, B., WATT, C. & EDELMAN, S.V. (1990). Reduced postprandial skeletal muscle blood flow contributes to glucose intolerance in human obesity. J. Clin. Endocrinol. Metab., 70, 1525-1533.
5. BRENMAN, J.E., CHAO, D.S., XIA, H., ALDAPE, K. & BREDT, D.S. (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell, 82, 743-752.
6. CLARK, M.G., WALLIS, M.G., BARRETT, E.J., VINCENT, M.A., RICHARDS, S.M., CLERK, L.H. & RATTIGAN, S. (2003). Blood flow and muscle metabolism: a focus on insulin action. Am. J. Physiol., 284, E241-E258.
7. EMMERSON, B.T., GORDON, R.B., CROSS, M. & THOMSON, D.B. (1987). Plasma oxipurinol concentrations during allopurinol therapy. Br. J. Rheumatol., 26, 445-449.
8. ETGEN, G.J.J., FRYBURG, D.A. & GIBBS, E.M. (1997). Nitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction-and phosphatidylinositol-3-kinase-independent pathway. Diabetes, 46, 1915-1919.
9. HIGAKI, Y., HIRSHMAN, M.F., FUJII, N. & GOODYEAR, L.J. (2001). Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. Diabetes, 50, 241-247.
10. INOUE, H., YANO, K., IKEO, T., NOTO, T. & KIKKAWA, K. (2001). T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats. Eur. J. Pharmacol., 422, 109-114.
11. JAMES, D.E., JENKINS, A.B. & KRAEGEN, E.W. (1985). Heterogeneity of insulin action in individual muscles in vivo: euglycemic clamp studies in rats. Am. J. Physiol., 248, E567-E574.
12. JARASCH, E.D., BRUDER, G. & HEID, H.W. (1986). Significance of xanthine oxidase in capillary endothelial cells. Acta Physiol. Scand., 548 (Suppl), 39-46.
13. KAPUR, S., BEDARD, S., MARCOTTE, B., COTE, C.H. & MARETTE, A. (1997). Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes, 46, 1691-1700.
14. KATAKAM, P.V., UJHELYI, M.R. & MILLER, A.W. (1999). EDHF-mediated relaxation is impaired in fructose-fed rats. J. Cardiovasc. Pharmacol., 34, 461-467.
15. KOBZIK, L., REID, M.B., BREDT, D.S. & STAMLER, J.S. (1994). Nitric oxide in skeletal muscle. Nature, 372, 546-548.
16. KOTERA, J., FUJISHIGE, K., MICHIBATA, H., YUASA, K., KUBO, A., NAKAMURA, Y. & OMORI, K. (2000). Characterization and effects of methyl-2-(4- aminophenyl)-1, 2-dihydro-1-oxo-7-(2-pyridinyl-methoxy)-4-(3,4,5- trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem. Pharmacol., 60, 1333-1341.
17. KRAEGEN, E.W., JAMES, D.E., JENKINS, A.B. & CHISHOLM, D.J. (1985). Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am. J. Physiol., 248, E353-E362.
18. LAU, K.S., GRANGE, R.W., ISOTANI, E., SARELIUS, I.H., KAMM, K.E., HUANG, P.L. & STULL, J.T. (2000). nNOS and eNOS modulate cGMP formation and vascular response in contracting fast-twitch skeletal muscle. Physiol. Genomics, 2, 21-27.
19. MAKINO, A., OHUCHI, K. & KAMATA, K. (2000). Mechanisms underlying the attenuation of endothelium-dependent vasodilatation in the mesenteric arterial bed of the streptozotocin-induced diabetic rat. Br. J. Pharmacol., 130, 549-556,
20. MINAMI, A., ISHIMURA, N., HARADA, N., SAKAMOTO, S., NIWA, Y. & NAKAYA, Y. (2002). Exercise training improves acetylcholine-induced endothelium-dependent hyperpolarization in type 2 diabetic rats, Otsuka Long-Evans Tokushima fatty rats. Atherosclerosis, 162, 85-92.
21. MOCHIDA, H., INOUE, H., TAKAGI, M., NOTO, T., YANO, K. & KIKKAWA, K. (2002). Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. Eur. J. Pharmacol., 440, 45-52.
22. OKUBO, K., KUSHIRO, T., TAKAHASHI, A. & KANMATSUSE, K. (1999). Role of endothelium-derived hyperpolarizing factor in insulin-induced vasodilation in rat mesenteric artery. Nippon Jinzo Gakkai Shi, 41, 685-691.
23. RATTIGAN, S., CLARK, M.G. & BARRETT, E.J. (1997). Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes, 46, 1381-1388.
24. RATTIGAN, S., CLARK, M.G. & BARRETT, E.J. (1999). Acute vasoconstriction-induced insulin resistance in rat muscle in vivo. Diabetes, 48, 564-569.
25. REID, M.B. (1998). Role of nitric oxide in skeletal muscle: synthesis, distribution and functional importance. Acta Physiol. Scand., 162, 401-409.
26. SAENZ, D.T., IANGULO, J., CUEVAS, P., FERNANDEZ, A., MONCADA, I., ALLONA, A., LLEDO, E., KORSCHEN, H.G., NIEWOHNER, U., HANING, H., PAGES, E. & BISCHOFF, E. (2001). The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. J. Impot. Res., 13, 282-290.
27. SHANKAR, R.R., WU, Y., SHEN, H.Q., ZHU, J.S. & BARON, A.D. (2000). Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes, 49, 684-687.
28. STAMLER, J.S. & MEISSNER, G. (2001). Physiology of nitric oxide in skeletal muscle. Physiol. Rev., 81, 209-237.
29. STEINBERG, H.O., BRECHTEL, G., JOHNSON, A., FINEBERG, N. & BARON, A.D. (1994). Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J. Clin. Investig., 94, 1172-1179.
30. VALLANCE, P. & MONCADA, S. (1994). Nitric oxide - from mediator to medicines. J. R. Coll. Physicians Lond., 28, 209-219.
31. VINCENT, M.A. & BARRETT, E.J. (2002). Insulin-induced capillary recruitment precedes changes in skeletal muscle glucose uptake. Diabetes, 51, A31.
32. VINCENT, M.A., BARRETT, E.J., LINDNER, J.R., CLARK, M.G. & RATTIGAN, S. (2003). Inhibiting NOS blocks microvascular recruitment and blunts glucose uptake in response to insulin. Am. J. Physiol., 285, E123-E129.
33. VINCENT, M.A., DAWSON, D., CLARK, A.D., LINDNER, J.R., RATTIGAN, S., CLARK, M.G. & BARRETT, E.J. (2002). Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes, 51, 42-48.
34. WALLIS, R.M., CORBIN, J.D., FRANCIS, S.H. & ELLIS, P. (1999). Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol., 83, 3C-12C.
35. WANG, P., WU, P., MYERS, J.G., STAMFORD, A., EGAN, R.W. & BILLAH, M.M. (2001). Characterization of human, dog and rabbit corpus cavernosum type 5 phosphodiesterases. Life Sci., 68, 1977-1987.
36. YKI-JARVINEN, H. & UTRIAINEN, T. (1998). Insulin-induced vasodilatation: physiology or pharmacology? Diabetologia, 41, 369-379.
37. YOUNG, M.E., CLARK, J.F. & LEIGHTON, B. (1997a). Zaprinast raises glucose utilisation in SHR skeletal muscle. Biochem. Soc. Trans., 25, 401S.
38. YOUNG, M.E. & LEIGHTON, B. (1998). Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem. J., 329, 73-79.
39. YOUNG, M.E., RADDA, G.K. & LEIGHTON, B. (1997b). Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem. J., 322, 223-228.